Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test Glioma Solid Tumor Gene Panel by NGS is 14 days.

What are the prerequisites for the test Glioma Solid Tumor Gene Panel by NGS

  • Specimen Type: Formalin-fixed paraffin-embedded (FFPE) tissue block or slides
  • Specimen Requirements: 10 unstained slides or 1 FFPE tissue block
  • Specimen Stability: FFPE blocks or slides should be stored at room temperature
  • Shipping Conditions: Ship at room temperature
  • Turnaround Time: 14-21 days
  • Preauthorization Required: No

What are the measure values for the test Glioma Solid Tumor Gene Panel by NGS

  • Gene Panel: Glioma Solid Tumor
  • Method: Next Generation Sequencing (NGS)
  • Measure Values:
    • Sequencing Depth: 500x
    • Coverage Uniformity: ≥ 95%
    • Variant Detection Sensitivity: ≥ 99%

What does this test Glioma Solid Tumor Gene Panel by NGS identify?

  • Glioma Solid Tumor Gene Panel by NGS identifies mutations in genes associated with gliomas, a type of brain tumor that originates in the glial cells of the brain.
  • The panel uses Next Generation Sequencing (NGS) technology to analyze multiple genes simultaneously, providing comprehensive information about the genetic alterations present in the tumor.
  • By identifying specific mutations in genes such as IDH1, IDH2, TP53, ATRX, and EGFR, the test helps in accurate diagnosis, prognosis, and personalized treatment planning for patients with glioma.
  • Additionally, the test may also detect other genetic changes that could influence the tumor's behavior and response to therapy, guiding healthcare providers in making informed decisions about patient care.

Why is this test Glioma Solid Tumor Gene Panel by NGS taken?

  • This test is taken to detect genetic mutations in patients with glioma solid tumors.
  • It helps in identifying specific genetic changes that may be driving the growth of the tumor.
  • The results of the test can guide treatment decisions, such as targeted therapy or clinical trials.
  • It can also provide information about the prognosis of the patient and help in monitoring the response to treatment.

No FAQs available.

Customer Google Rating